

---

FOR IMMEDIATE RELEASE:

Contact: Dianne Chase  
704-442-9199 (o)  
704-606-1144 (c)  
dianne@alacartepr.com

---

## **MD SCIENTIFIC, LLC ANNOUNCES ISSUANCE OF U.S. PATENT NO. 7,019,035**

Charlotte, NC – March 31, 2006 – MD Scientific, LLC, a North Carolina limited liability company, announces the issuance of a United States patent for the method of preventing acute kidney failure from the use of iodinated contrast agents. Use of this patented method to prevent acute kidney failure caused by the use of iodinated contrast agents could potentially save the healthcare industry several billion dollars annually.

“This method is ‘new thinking’ in medicine and provides a unique opportunity to save lives and improve outcomes by using a drug generally recognized as safe with the patented method,” states Dr. W. Patrick Burgess, MD, PhD, and Medical Director of MD Scientific.

MD Scientific is also working toward initiating and completing a Phase III clinical study to obtain FDA approval to manufacture the drug in a safe, convenient, and economical form for distribution. In the interim, MD Scientific will offer health institutions a licensing opportunity to use the patented Method until the drug is commercially available.

Iodinated contrast agents are commonly used for diagnostic and therapeutic procedures in conjunction with various X-Ray devices including:

- [Computerized Tomographic \(“CT”\) scan enhancement](#)
- [Arteriograms](#)
- [Cardiac catheterization](#)
- [Vascular studies](#)
- [Arterial intervention – angioplasty and stent](#)
- [Venous intervention - angioplasty and stent](#)
- [Cerebral angiography](#)
- [Peripheral arteriography](#)
- [Venography](#)
- [Selective visceral arteriography](#)
- [Digital subtraction angiography](#)
- [Urography](#)
- [Computer tomography angiography \(“CTA”\)](#)

Acute kidney failure from the administration of iodinated contrast agents is commonly referred to as Contrast-Induced Nephropathy (“CIN”). MD Scientific’s United States patent describing the methodology of using bicarbonate (intravenous solution and oral preparations) for the reduction or prevention of CIN was issued on March 28, 2006. One embodiment of this method of preventing CIN is described in a May 19, 2004 article in the Journal of American Medical Association (JAMA) titled “Prevention of Contrast-Induced Nephropathy with Sodium Bicarbonate”.

### About MD Scientific, LLC:

MD Scientific, LLC was formed in September 2003 for the purpose of developing and commercializing a drug for the prevention of acute renal failure and software to calculate insulin dosage for critically ill patients with elevated blood glucose.

For additional information, contact:  
Shade M. Mecum, President, CEO  
704-335-1300  
704-335-1309 (fax)  
shademecum@mdsci.com